LAUSR

In this special issue of the Magazine of EuropeanMedical Oncology (MEMO) clinical experts are summarizing the most relevant topics regarding the management and treatment of sarcoma patients. Collectively, their message is clear—a centralized multidisciplinary tumour board is crucial to enhance outcome of sarcoma patients. In her short review, Liegl-Atzwanger [1] provides insight into the highly complex field of sarcoma pathology that is characterized by high heterogeneity despite the low incidence of this disease. Specimen referral to a pathologist specialized in sarcomas is mandatory and of utmost importance to make an exact diagnosis which has important treatment-specific consequences. Windhager et al. [2] present the central role of limbsparing surgery and highlight the importance of adequate R0 resection, which has an impact on the prognosis and survival of patients. Moreover, the authors describe high-level activity, such as sports, as a new potential scoring system to evaluate quality of life after limb-sparing surgery. Next, Roeder [3] and Rothermundt [4] provide an in-depth review of perioperative radioand chemotherapeutic strategies. Radiotherapy and chemotherapy are an integral part in multimodal treatment concepts for sarcoma patients. In a multidisciplinary tumour board, the use of those multimodal approaches should be discussed to increase, in addition to the local control rate, the relapse-free and overall survival. Especially, for patients with a highrisk profile neoadjuvant chemoor radiotherapy, in-